cMyC®

Cardiac Specific Biomarker

Patented biomarker for cardiac injury. 

cMyC®

Cardiac Specific Biomarker

Patented biomarker for cardiac injury. 

Phosphorylation and fragmentation pattern of cMyC for the differentiation between different types of myocardial injury

  • Bashir Alaour, Yu Jin Chung, Thomas Edward Kaier, Jasmine India Helen Quraishi, Helen Heath, Zilan Demir, Sakthivel Sadayappan, Simon R. Redwood, Brian Raymond Weil, John M. Canty, and Michael S. Marber
  • JACC Journal of the American College of Cardiology
Go to original publication...

Background

Cardiac myosin-binding protein C (cMyC) is a novel biomarker of myocardial injury. We hypothesize that Calpain-mediated cleavage of cMyC is dependent on its phosphorylation status and can aid the differentiation between different types of myocardial injury

Conclusion

Phosphorylation and fragmentation pattern of cMyC are dependent on the type of myocardial injury and might aid the differentiation between Type-1 and non-Type-1 AMI
Human serum showed higher ratio of intact to total (all species) cMyC in Type 2- vs Type 1-AMI
Human serum showed higher ratio of intact to total (all species) cMyC in Type 2- vs Type 1-AMI
Go to original publication...
Click here for an overview of all publications
Categories
Tags